All updates
All updates
today 53The Lancet精选评分6464 文献与产业新闻精选评分5454 Kodiak challenges Eylea with a six-month dosing interval in wet AMD
BioPharma Dive精选评分5757 Kodiak skyrockets on positive study data for 2 eye drugs
BioPharma Dive精选评分4747 An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
BioSpace评分5252 Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
监管与产业动态精选评分4444 Roche drops muscle-sparing obesity antibody after flunked interim analysis - Fierce Biotech
监管与产业动态评分2929 Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir - Fierce Biotech
监管与产业动态精选评分3636 Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3 - Fierce Biotech
中文产业新闻精选Chinese source评分6565 瑞金医院与艾博生物合作开发mRNA编码TCE ABO2203，3例难治性ITP患者达完全缓解
监管与产业动态评分3131 Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches - Fierce Biotech
中文产业新闻精选Chinese source评分7272 依沃西单抗对比帕博利珠单抗在PD-L1阳性晚期非小细胞肺癌一线治疗中显示生存优势
监管与产业动态评分1313 Signal or noise? > Retina Society 2026: Exudate control similar in Coats disease and Coats-like disease in inherited retinal diseases - Ophthalmology Times >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #healthcare #pharma #competitivemarketing
NEJM评分1212 Serotonin Syndrome
监管与产业动态评分2222 Signal or noise? > Ocugen's OCU410 gene therapy slows geographic atrophy lesion growth by up to 32% in Phase 2 - Dealroom >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #competitivemarketing #pharmaceutical #pharma
The Lancet Oncology精选评分6969 [Articles] Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
BioSpace精选评分5353 J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
中文产业新闻精选Chinese source评分6464 传奇生物CARVYKTI在CARTITUDE-2队列A中显示50% RRMM患者单次输注五年后无进展生存
The Lancet精选评分5555 [Articles] Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial
中文产业新闻精选Chinese source评分6060 诺和诺德CagriSema在头对头试验中减重效果优于替尔泊肽
中文产业新闻精选Chinese source评分6868 诺和诺德CagriSema头对头替尔泊肽的Ⅲ期REIMAGINE 5研究达到主要终点
文献与产业新闻评分2323 A clinical study on the efficacy of a novel herbal medicine cocktail in enhancing HIFU treatment for adenomyosis: a pilot randomized controlled trial
文献与产业新闻精选评分4444 Sequential combination of anti-PD-1 antibody and PEG-IFNα in chronic hepatitis B patients: correlates of HBsAg loss with enhanced T-cell responses
中文产业新闻精选Chinese source评分6060 默沙东 FZD4/LRP5 双抗治疗 DME 的 2b/3 期临床试验成功
medRxiv Oncology精选评分5656 Tumour extrinsic neutrophil regulation in mesothelioma correlates with responsiveness to AXL and PD1 inhibition in MIST3, a phase IIA clinical trial
The Lancet精选评分4747 [Articles] Faecal microbiota transplantation in irritable bowel syndrome (REFIT2): a randomised, double-blind, placebo-controlled, phase 3 trial
文献与产业新闻评分3434 STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit
文献与产业新闻精选评分5656 Merck sees pivotal victory for $3B eye disease prospect
文献与产业新闻精选评分5656 Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial
中文产业新闻精选Chinese source评分6060 免疫细胞改写肝硬化治疗格局：无移植生存期延长252天
文献与产业新闻精选评分5858 Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
文献与产业新闻精选评分5959 Immunovant ends cutaneous lupus program after phase 2 flop
中文产业新闻精选Chinese source评分6868 罗氏与Ionis的Sefaxersen治疗IgA肾病III期研究达到主要终点
NEJM精选评分6262 Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome
NEJM精选评分4545 Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma
NEJM评分1010 Case 27-2026: A 4-Year-Old Boy with Fatigue, Imbalance, and Frequent Falls
NEJM评分00 Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection
NEJM评分00 Anito-cel for Multiple Myeloma
文献与产业新闻精选评分5858 Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
Science Translational Medicine评分00 Preclinical and clinical evaluation of systemic danegaptide for the treatment of nonproliferative diabetic retinopathy
文献与产业新闻评分2424 An antibody–drug conjugate for small-cell lung cancer